Profile - To The Moon

ahhshan

Posts · 19Posts · 19
Following · 0Following · 0
Followers · 0Followers · 0

- ahhshanahhshan
  ·2022-04-28
  Good
  Moderna Asks FDA to Clear Its Covid-19 Vaccine for Young Children
  Shot has been tested for kids aged 6 months to 5 years, a group not yet eligible for vaccination in
  Moderna Asks FDA to Clear Its Covid-19 Vaccine for Young Children
  1.15K Comment
  Like
  Share
  Report
- ahhshanahhshan
  ·2021-07-24
  Thanks
  Sorry, this post has been deleted
  2.04K Comment
  2
  Share
  Report
- ahhshanahhshan
  ·2021-07-12
  Clov?
  Sorry, this post has been deleted
  1.49K Comment
  2
  Share
  Report
- ahhshanahhshan
  ·2021-06-29
  Omg
  Sorry, this post has been deleted
  1.79K Comment
  Like
  Share
  Report
- ahhshanahhshan
  ·2021-06-24
  Amen
  Sorry, this post has been deleted
  1.46K Comment
  4
  Share
  Report
- ahhshanahhshan
  ·2021-06-23
  Nio vs xpeng
  Sorry, this post has been deleted
  1.75K Comment
  1
  Share
  Report
- ahhshanahhshan
  ·2021-06-21
  Meme stocks are the best
  Sorry, this post has been deleted
  1.12K Comment
  Like
  Share
  Report
- ahhshanahhshan
  ·2021-06-20
  Diamond hands! Endure, it will be over soon.
  Sorry, this post has been deleted
  2.00K Comment
  3
  Share
  Report
- ahhshanahhshan
  ·2021-06-19
  Bull
  Sorry, this post has been deleted
  2.20K 2
  4
  Share
  Report
- ahhshanahhshan
  ·2021-06-18
  Lets go
  Toplines Before US Market Open on Friday
  U.S. stock futures fell on Friday as the S&P 500 and the Dow Jones Industrial Average are on pace to
  Toplines Before US Market Open on Friday
  1.59K Comment
  2
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3584827494956837","uuid":"3584827494956837","gmtCreate":1621734140183,"gmtModify":1637031914866,"name":"ahhshan","pinyin":"ahhshan","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":12,"tweetSize":19,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.35%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9060204033,"gmtCreate":1651150580662,"gmtModify":1676534859084,"author":{"id":"3584827494956837","authorId":"3584827494956837","name":"ahhshan","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584827494956837","idStr":"3584827494956837"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9060204033","repostId":"1141941800","repostType":4,"repost":{"id":"1141941800","kind":"news","pubTimestamp":1651145715,"share":"https://ttm.financial/m/news/1141941800?lang=&edition=fundamental","pubTime":"2022-04-28 19:35","market":"us","language":"en","title":"Moderna Asks FDA to Clear Its Covid-19 Vaccine for Young Children","url":"https://stock-news.laohu8.com/highlight/detail?id=1141941800","media":"The Wall Street Journal","summary":"Shot has been tested for kids aged 6 months to 5 years, a group not yet eligible for vaccination in ","content":"<html><head></head><body><p>Shot has been tested for kids aged 6 months to 5 years, a group not yet eligible for vaccination in the U.S.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5e662438db1844dd05f0714dfc242a7a\" tg-width=\"1290\" tg-height=\"859\" width=\"100%\" height=\"auto\"/><span>A youngster participated in Moderna’s Covid-19 vaccine trial late last year.</span></p><p>Moderna Inc. has asked U.S. health regulators to authorize the use of its Covid-19 vaccine in children ages 6 months to 5 years old.</p><p>The company said Thursday that it had submitted the request after a study showed the shot safely induced immune responses in the young age group.</p><p>If the regulators agree, one of the last remaining age groups still not eligible for Covid-19 vaccination in the U.S.—children under 5 years—could begin to receive the shots by summer.</p><p>The Food and Drug Administration is expected to convene a public meeting of a panel of outside vaccine advisers within weeks to consider Moderna’s request. An FDA official said at a recent congressional hearing the agency would move quickly once it had a completed application, and would release a schedule for advisory panel meetings within the next week.</p><p>If the panel votes to recommend the shot, the FDA could authorize its use soon after, though the agency may seek additional data before making a decision. The FDA has delayed authorizing Moderna’s vaccine — mRNA-1273, or Spikevax—for adolescents to assess whether the shots heighten the risk of aninflammatory heart condition.</p><p>Some parents of young children have been clamoring for an authorized vaccine.</p><p>The other leading Covid-19 vaccine from Pfizer Inc. and BioNTech SE is authorized for anyone 5 years and older, while Moderna’s has only been cleared for adults 18 and older in the U.S.</p><p>“Every day that these kids go without vaccination is another opportunity to get severe disease, to get hospitalized, to get long Covid, so I think there is a need to make this available to children,” Moderna Chief Medical OfficerPaul Burtonsaid in an interview.</p><p>To support its application for authorization in adolescents, Moderna said it has provided the FDA additional safety and efficacy data in the age group. Moderna also has started the process of seeking authorization of use of its vaccine in children ages 6 to 11.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6391f076ae9406477b9d6dee521cab03\" tg-width=\"1050\" tg-height=\"701\" width=\"100%\" height=\"auto\"/><span>The vaccine from Pfizer and BioNTech is authorized for anyone 5 years and older.</span></p><p>Covid-19 cases in children tend to be milder than for adults, but there have been severe cases resulting in hospitalizations and deaths, especially during the Omicron wave during the winter.</p><p>Efforts to widen the Covid-19 vaccination campaign to include children under 5 years have hit setbacks in recent months, frustrating some parents who want their young kids vaccinated.</p><p>On April 24, a group of parents and doctors named Protect Their Future filed a citizen petition with the FDA urging the agency to immediately review any application for use of a vaccine in children under 5 years.</p><p>Kailey Soller said she has been cautious about where she takes her 18-month-old daughter because the toddler is unvaccinated.</p><p>“As long as the safety profile looks good for the vaccine, I would vaccinate her,” Ms. Soller, of Chanhassen, Minn., said in an interview. “Once she is vaccinated, we will resume life much more normally. We would feel more comfortable bringing her to a Target, going on vacation.”</p><p>The FDA in February delayed a decision on the use of the Pfizer-BioNTech vaccine in children under 5 years after the companies got mixed results in clinical testing.</p><p>The delay came after two doses of the Pfizer-BioNTech vaccine didn’t produce a strong immune response in 2- to 4-year-olds, but did so in children under 2 years. The companies are waiting for additional results to see whether providing a third dose improves the immune response.</p><p>A Kaiser Family Foundation poll in February found that 21% of parents with children under 5 years plan to get them vaccinated right away. But many parents have no intention of vaccinating their young children, with the same poll finding that 35% of those surveyed said they won’t vaccinate their kids.</p><p>Some parents have expressed concern about the safety of the vaccine. The vaccines from Moderna and Pfizer have been associated with an increased risk of heart-inflammation conditions including myocarditis, especially in males under the age of 30, U.S. health authorities say.</p><p>The risk of severe Covid-19 is much lower in children than in older adults, but there is still a level of risk that infectious-disease specialists say warrants vaccination.</p><p>Some studies have found that the risk of myocarditis after vaccination is lower than the risk of developing myocarditis after Covid-19 infection.</p><p>Covid-related hospitalization rates for children in the U.S. rose sharply during the winter surge of Covid-19 cases caused by the Omicron variant, according to the Centers for Disease Control and Prevention. In January, weekly Covid-19 hospitalization rates of children under 5 peaked at about 14.5 per 100,000 children, which was about five times the peak rate during the Delta variant surge, the CDC said.</p><p>“Children of any age can become ill with Covid, with those under a year of age and those with underlying conditions being at the greatest risk for severe disease and complications,” said Dr. Tina Tan, professor of pediatrics at Northwestern University Feinberg School of Medicine.</p><p>About 28% of children ages 5 to 11 and 59% of adolescents 12 to 17 have received the full primary vaccination series of two doses,according to the CDC. Overall, 70% of the eligible U.S. population has been fully vaccinated.</p><p>Moderna is seeking authorization of a dosage of its vaccine in young children that is one-fourth the amount used for adults. Moderna found in a study that two doses of the vaccine safely induced immune responses in children that were comparable to immune responses seen in young adults.</p><p>The study found the shot was 43.7% effective against symptomatic Covid-19 infections in children ages 6 months to 2 years, and 37.5% effective in those ages 2 to 5.</p><p>Moderna said Thursday that those efficacy figures included cases diagnosed with at-home Covid tests during the Omicron surge. When the analysis is limited only to cases confirmed positive by a central laboratory test, the vaccine was 51% effective in children 6 months to 2 years, and 37% in the older group, the company said.</p><p>The company reported these results in a press release. The data haven’t been published in a peer-review journal.</p><p>The efficacy rates in children are lower than the 94% efficacy Moderna’s vaccine demonstrated against symptomatic disease in a large study of adults in 2020. But that study was conducted before the more-transmissible Omicron variant, and Moderna said the efficacy in adults against symptomatic disease caused by Omicron is comparable to the rates seen in the pediatric study.</p><p>The company said many of the cases took place during the Omicron variant wave in the winter. Covid-19 vaccines generally had lower efficacy against symptomatic infections caused by the highly contagious Omicron variant, though they continued to reduce risk of hospitalization and death, particularly among people who got a booster shot.</p><p>Moderna said the majority of cases of symptomatic Covid-19 in the study of young children were mild. There were no severe Covid-19 cases—including hospitalizations and deaths—in any children in the study. As a result, Moderna wasn’t able to assess the efficacy of the vaccine in young children against severe cases including hospitalizations.</p><p>Most side effects, like injection-site pain and fever, were mild or moderate, Moderna said. The company observed no new safety concerns, and there were no deaths, myocarditis or cases of an inflammatory syndrome in children reported in the study, Moderna said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Asks FDA to Clear Its Covid-19 Vaccine for Young Children</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Asks FDA to Clear Its Covid-19 Vaccine for Young Children\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-28 19:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/moderna-asks-fda-to-clear-its-covid-19-vaccine-for-young-children-11651143600?mod=hp_lead_pos3><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shot has been tested for kids aged 6 months to 5 years, a group not yet eligible for vaccination in the U.S.A youngster participated in Moderna’s Covid-19 vaccine trial late last year.Moderna Inc. has...</p>\n\n<a href=\"https://www.wsj.com/articles/moderna-asks-fda-to-clear-its-covid-19-vaccine-for-young-children-11651143600?mod=hp_lead_pos3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.wsj.com/articles/moderna-asks-fda-to-clear-its-covid-19-vaccine-for-young-children-11651143600?mod=hp_lead_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141941800","content_text":"Shot has been tested for kids aged 6 months to 5 years, a group not yet eligible for vaccination in the U.S.A youngster participated in Moderna’s Covid-19 vaccine trial late last year.Moderna Inc. has asked U.S. health regulators to authorize the use of its Covid-19 vaccine in children ages 6 months to 5 years old.The company said Thursday that it had submitted the request after a study showed the shot safely induced immune responses in the young age group.If the regulators agree, one of the last remaining age groups still not eligible for Covid-19 vaccination in the U.S.—children under 5 years—could begin to receive the shots by summer.The Food and Drug Administration is expected to convene a public meeting of a panel of outside vaccine advisers within weeks to consider Moderna’s request. An FDA official said at a recent congressional hearing the agency would move quickly once it had a completed application, and would release a schedule for advisory panel meetings within the next week.If the panel votes to recommend the shot, the FDA could authorize its use soon after, though the agency may seek additional data before making a decision. The FDA has delayed authorizing Moderna’s vaccine — mRNA-1273, or Spikevax—for adolescents to assess whether the shots heighten the risk of aninflammatory heart condition.Some parents of young children have been clamoring for an authorized vaccine.The other leading Covid-19 vaccine from Pfizer Inc. and BioNTech SE is authorized for anyone 5 years and older, while Moderna’s has only been cleared for adults 18 and older in the U.S.“Every day that these kids go without vaccination is another opportunity to get severe disease, to get hospitalized, to get long Covid, so I think there is a need to make this available to children,” Moderna Chief Medical OfficerPaul Burtonsaid in an interview.To support its application for authorization in adolescents, Moderna said it has provided the FDA additional safety and efficacy data in the age group. Moderna also has started the process of seeking authorization of use of its vaccine in children ages 6 to 11.The vaccine from Pfizer and BioNTech is authorized for anyone 5 years and older.Covid-19 cases in children tend to be milder than for adults, but there have been severe cases resulting in hospitalizations and deaths, especially during the Omicron wave during the winter.Efforts to widen the Covid-19 vaccination campaign to include children under 5 years have hit setbacks in recent months, frustrating some parents who want their young kids vaccinated.On April 24, a group of parents and doctors named Protect Their Future filed a citizen petition with the FDA urging the agency to immediately review any application for use of a vaccine in children under 5 years.Kailey Soller said she has been cautious about where she takes her 18-month-old daughter because the toddler is unvaccinated.“As long as the safety profile looks good for the vaccine, I would vaccinate her,” Ms. Soller, of Chanhassen, Minn., said in an interview. “Once she is vaccinated, we will resume life much more normally. We would feel more comfortable bringing her to a Target, going on vacation.”The FDA in February delayed a decision on the use of the Pfizer-BioNTech vaccine in children under 5 years after the companies got mixed results in clinical testing.The delay came after two doses of the Pfizer-BioNTech vaccine didn’t produce a strong immune response in 2- to 4-year-olds, but did so in children under 2 years. The companies are waiting for additional results to see whether providing a third dose improves the immune response.A Kaiser Family Foundation poll in February found that 21% of parents with children under 5 years plan to get them vaccinated right away. But many parents have no intention of vaccinating their young children, with the same poll finding that 35% of those surveyed said they won’t vaccinate their kids.Some parents have expressed concern about the safety of the vaccine. The vaccines from Moderna and Pfizer have been associated with an increased risk of heart-inflammation conditions including myocarditis, especially in males under the age of 30, U.S. health authorities say.The risk of severe Covid-19 is much lower in children than in older adults, but there is still a level of risk that infectious-disease specialists say warrants vaccination.Some studies have found that the risk of myocarditis after vaccination is lower than the risk of developing myocarditis after Covid-19 infection.Covid-related hospitalization rates for children in the U.S. rose sharply during the winter surge of Covid-19 cases caused by the Omicron variant, according to the Centers for Disease Control and Prevention. In January, weekly Covid-19 hospitalization rates of children under 5 peaked at about 14.5 per 100,000 children, which was about five times the peak rate during the Delta variant surge, the CDC said.“Children of any age can become ill with Covid, with those under a year of age and those with underlying conditions being at the greatest risk for severe disease and complications,” said Dr. Tina Tan, professor of pediatrics at Northwestern University Feinberg School of Medicine.About 28% of children ages 5 to 11 and 59% of adolescents 12 to 17 have received the full primary vaccination series of two doses,according to the CDC. Overall, 70% of the eligible U.S. population has been fully vaccinated.Moderna is seeking authorization of a dosage of its vaccine in young children that is one-fourth the amount used for adults. Moderna found in a study that two doses of the vaccine safely induced immune responses in children that were comparable to immune responses seen in young adults.The study found the shot was 43.7% effective against symptomatic Covid-19 infections in children ages 6 months to 2 years, and 37.5% effective in those ages 2 to 5.Moderna said Thursday that those efficacy figures included cases diagnosed with at-home Covid tests during the Omicron surge. When the analysis is limited only to cases confirmed positive by a central laboratory test, the vaccine was 51% effective in children 6 months to 2 years, and 37% in the older group, the company said.The company reported these results in a press release. The data haven’t been published in a peer-review journal.The efficacy rates in children are lower than the 94% efficacy Moderna’s vaccine demonstrated against symptomatic disease in a large study of adults in 2020. But that study was conducted before the more-transmissible Omicron variant, and Moderna said the efficacy in adults against symptomatic disease caused by Omicron is comparable to the rates seen in the pediatric study.The company said many of the cases took place during the Omicron variant wave in the winter. Covid-19 vaccines generally had lower efficacy against symptomatic infections caused by the highly contagious Omicron variant, though they continued to reduce risk of hospitalization and death, particularly among people who got a booster shot.Moderna said the majority of cases of symptomatic Covid-19 in the study of young children were mild. There were no severe Covid-19 cases—including hospitalizations and deaths—in any children in the study. As a result, Moderna wasn’t able to assess the efficacy of the vaccine in young children against severe cases including hospitalizations.Most side effects, like injection-site pain and fever, were mild or moderate, Moderna said. The company observed no new safety concerns, and there were no deaths, myocarditis or cases of an inflammatory syndrome in children reported in the study, Moderna said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174457144,"gmtCreate":1627131552588,"gmtModify":1703484641416,"author":{"id":"3584827494956837","authorId":"3584827494956837","name":"ahhshan","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584827494956837","idStr":"3584827494956837"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/174457144","repostId":"2153981075","repostType":4,"isVote":1,"tweetType":1,"viewCount":2042,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146132983,"gmtCreate":1626057913342,"gmtModify":1703752518134,"author":{"id":"3584827494956837","authorId":"3584827494956837","name":"ahhshan","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584827494956837","idStr":"3584827494956837"},"themes":[],"htmlText":"Clov?","listText":"Clov?","text":"Clov?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/146132983","repostId":"2150530903","repostType":4,"isVote":1,"tweetType":1,"viewCount":1494,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159250085,"gmtCreate":1624971659747,"gmtModify":1703849086387,"author":{"id":"3584827494956837","authorId":"3584827494956837","name":"ahhshan","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584827494956837","idStr":"3584827494956837"},"themes":[],"htmlText":"Omg","listText":"Omg","text":"Omg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159250085","repostId":"2146388793","repostType":4,"isVote":1,"tweetType":1,"viewCount":1788,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126084136,"gmtCreate":1624537770025,"gmtModify":1703839692828,"author":{"id":"3584827494956837","authorId":"3584827494956837","name":"ahhshan","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584827494956837","idStr":"3584827494956837"},"themes":[],"htmlText":"Amen","listText":"Amen","text":"Amen","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126084136","repostId":"1195543409","repostType":4,"isVote":1,"tweetType":1,"viewCount":1459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121939474,"gmtCreate":1624448180298,"gmtModify":1703836968532,"author":{"id":"3584827494956837","authorId":"3584827494956837","name":"ahhshan","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584827494956837","idStr":"3584827494956837"},"themes":[],"htmlText":"Nio vs xpeng","listText":"Nio vs xpeng","text":"Nio vs xpeng","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121939474","repostId":"1145825451","repostType":4,"isVote":1,"tweetType":1,"viewCount":1745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164443809,"gmtCreate":1624234646101,"gmtModify":1703830999412,"author":{"id":"3584827494956837","authorId":"3584827494956837","name":"ahhshan","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584827494956837","idStr":"3584827494956837"},"themes":[],"htmlText":"Meme stocks are the best","listText":"Meme stocks are the best","text":"Meme stocks are the best","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164443809","repostId":"2145470425","repostType":4,"isVote":1,"tweetType":1,"viewCount":1116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165796487,"gmtCreate":1624156925849,"gmtModify":1703829673701,"author":{"id":"3584827494956837","authorId":"3584827494956837","name":"ahhshan","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584827494956837","idStr":"3584827494956837"},"themes":[],"htmlText":"Diamond hands! Endure, it will be over soon.","listText":"Diamond hands! Endure, it will be over soon.","text":"Diamond hands! Endure, it will be over soon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/165796487","repostId":"1126454279","repostType":4,"isVote":1,"tweetType":1,"viewCount":1996,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162269163,"gmtCreate":1624064907352,"gmtModify":1703827922370,"author":{"id":"3584827494956837","authorId":"3584827494956837","name":"ahhshan","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584827494956837","idStr":"3584827494956837"},"themes":[],"htmlText":"Bull","listText":"Bull","text":"Bull","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/162269163","repostId":"1138062216","repostType":4,"isVote":1,"tweetType":1,"viewCount":2202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166474462,"gmtCreate":1624024137956,"gmtModify":1703826870761,"author":{"id":"3584827494956837","authorId":"3584827494956837","name":"ahhshan","avatar":"https://static.tigerbbs.com/78d234f67fb47c77be871438197cf87c","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584827494956837","idStr":"3584827494956837"},"themes":[],"htmlText":"Lets go","listText":"Lets go","text":"Lets go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166474462","repostId":"1147049745","repostType":4,"repost":{"id":"1147049745","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624018214,"share":"https://ttm.financial/m/news/1147049745?lang=&edition=fundamental","pubTime":"2021-06-18 20:10","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1147049745","media":"Tiger Newspress","summary":"U.S. stock futures fell on Friday as the S&P 500 and the Dow Jones Industrial Average are on pace to","content":"<p>U.S. stock futures fell on Friday as the S&amp;P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&amp;P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25234fe10c0fe8a9e73f2cec66447216\" tg-width=\"1003\" tg-height=\"316\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>The blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&amp;P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.</p>\n<p>The decline in stocks came amid a drastic flattening of the so-called Treasury yield curve&nbsp;where the yields of shorter-duration Treasurys, like the&nbsp;2-year note, rose, while longer duration yields, such as the benchmark 10-year fell.&nbsp;The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.</p>\n<p>The central bank's hawkish pivot on Wednesday&nbsp;caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.</p>\n<p>Friday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Adobe(ADBE) </b>– Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.</p>\n<p><b>Smith &amp; Wesson(SWBI) </b>– Smith &amp; Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.</p>\n<p><b>Orphazyme(ORPH)</b> – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.</p>\n<p><b>Delta Air Lines(DAL)</b> – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.</p>\n<p><b>Manchester United(MANU) </b>– Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.</p>\n<p><b>ArcelorMittal(MT) </b>– ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.</p>\n<p><b>Carnival(CCL) </b>– The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.</p>\n<p><b>Fox Corp.(FOXA) </b>– Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.</p>\n<p><b>Pilgrim's Pride(PPC) </b>– Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.</p>\n<p><b>Hasbro(HAS),Mattel(MAT) </b>– The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.</p>\n<p><b>Biogen(BIIB)</b> – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.</p>\n<p><b>Citigroup(C) </b>– The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-18 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock futures fell on Friday as the S&amp;P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&amp;P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25234fe10c0fe8a9e73f2cec66447216\" tg-width=\"1003\" tg-height=\"316\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>The blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&amp;P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.</p>\n<p>The decline in stocks came amid a drastic flattening of the so-called Treasury yield curve&nbsp;where the yields of shorter-duration Treasurys, like the&nbsp;2-year note, rose, while longer duration yields, such as the benchmark 10-year fell.&nbsp;The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.</p>\n<p>The central bank's hawkish pivot on Wednesday&nbsp;caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.</p>\n<p>Friday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Adobe(ADBE) </b>– Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.</p>\n<p><b>Smith &amp; Wesson(SWBI) </b>– Smith &amp; Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.</p>\n<p><b>Orphazyme(ORPH)</b> – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.</p>\n<p><b>Delta Air Lines(DAL)</b> – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.</p>\n<p><b>Manchester United(MANU) </b>– Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.</p>\n<p><b>ArcelorMittal(MT) </b>– ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.</p>\n<p><b>Carnival(CCL) </b>– The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.</p>\n<p><b>Fox Corp.(FOXA) </b>– Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.</p>\n<p><b>Pilgrim's Pride(PPC) </b>– Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.</p>\n<p><b>Hasbro(HAS),Mattel(MAT) </b>– The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.</p>\n<p><b>Biogen(BIIB)</b> – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.</p>\n<p><b>Citigroup(C) </b>– The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147049745","content_text":"U.S. stock futures fell on Friday as the S&P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.\nAt 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.\n*Source From Tiger Trade, EST 08:05\nThe blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.\nThe decline in stocks came amid a drastic flattening of the so-called Treasury yield curve where the yields of shorter-duration Treasurys, like the 2-year note, rose, while longer duration yields, such as the benchmark 10-year fell. The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.\nThe central bank's hawkish pivot on Wednesday caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.\nFriday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.\nStocks making the biggest moves in the premarket:\nAdobe(ADBE) – Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.\nSmith & Wesson(SWBI) – Smith & Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.\nOrphazyme(ORPH) – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.\nDelta Air Lines(DAL) – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.\nManchester United(MANU) – Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.\nArcelorMittal(MT) – ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.\nCarnival(CCL) – The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.\nFox Corp.(FOXA) – Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.\nPilgrim's Pride(PPC) – Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.\nHasbro(HAS),Mattel(MAT) – The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.\nBiogen(BIIB) – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.\nCitigroup(C) – The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":1586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}